Case Study:
Finding New Insights Why Physicians Are Increasing or Decreasing their Prescribing of a Specific Brand Using AI
Finding New Insights Why Physicians Are Increasing or Decreasing their Prescribing of a Specific Brand Using AI
Typically when aiming to understand why a physician is increasing or decreasing their prescribing of a specific brand, marketers turn to market research. This has its’ limits due to sample and bias. This client wanted to use real world data to uncover previously unseen insights.
The Client
The client had conducted market research but it failed to explain some of the increases and decreases seen and they wanted to get a more granular real world data insight into some of the prescribing changes seen.
The Solution
They decided to turn to Artificial Intelligence to see if real world data could explain some of the things seen. We were able to access Prescribing data by physician on a monthly basis. On top of that we also had claims data which we could link to the physician, as well as physician profile data from AMA. This combination of data allowed us to find patterns in the data that shed some light on some of the prescribing changes. For example some physicians were constrained by their health plans which impacted this client brand, some geographic locations led to higher prescribing on brands (and we were able to then look at company internal data to understand some of the reasons behind this based on their activity),
The Outcome
A clearer understanding of some of the prescribing behaviour could be identified and the company then could develop plans to address them.
To achieve these kinds of results, contact Eularis today.
Latest News
Read our latest blogs here.

We Have AI Initiatives. But, Do We Have a Strategy?
Every week, I speak with executives who tell me the same thing with the same mixture of pride and quiet unease: “We’re investing heavily in

Pharma’s Patent Cliff is Here. Why AI Strategy Matters Now More Than Ever.
The pharmaceutical industry is entering a decisive period. Over the next several years, many of its most valuable brands will lose exclusivity, putting a substantial

The Hidden Cost of Having No AI Strategy (Spoiler: It’s Not What You Think)
In the past few years, almost 70% of biopharma companies have initiated AI initiatives. Yet, fewer than 20% report a cohesive AI strategy at the